NCT00492440TerminatedPhase 1
A Phase I Study of Subcutaneous "CYT 107" (Interleukin-7) in Refractory Metastatic Melanoma or Renal Cell Carcinoma
Conditions
Interventions
Trial Snapshot
- Phase
- Phase 1
- Status
- Terminated
- Sponsor
- Cytheris SA
- Enrollment
- 9
- Locations
- 1
- Primary Endpoint
- Safety of recombinant interleukin-7 (IL-7)
Study Overview
Brief Summary
RATIONALE: Interleukin-7 may stimulate the white blood cells to kill tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of interleukin-7 in treating patients with metastatic melanoma or locally advanced or metastatic kidney cancer.
Detailed Description
OBJECTIVES:
Primary
- Determine the safety of recombinant interleukin-7 (IL-7) in patients with metastatic melanoma or locally advanced or metastatic renal cell carcinoma.
- Confirm the previously documented safety profile of non-glycosylated IL-7 in these patients.
- Determine the safety of higher doses of recombinant IL-7 in these patients.
- Determine the maximum tolerated dose of recombinant IL-7 in these patients.
- Determine the biologically active dose of recombinant IL-7 in these patients.
Secondary
- Determine the pharmacokinetics and pharmacodynamics of recombinant IL-7 in these patients.
- Compare the biological and clinical effects of recombinant IL-7 with non-glycosylated IL-7 in these patients.
- Determine the potential antitumor effect of recombinant IL-7 in these patients.
- Determine the dose and administration schedule of recombinant IL-7 in these patients.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •DISEASE CHARACTERISTICS:
- •Histologically confirmed diagnosis of 1 of the following:
- •Metastatic disease
- •Renal cell carcinoma
- •Locally advanced and unresectable disease OR metastatic disease
- •Refractory to standard therapy OR ineligible to receive standard therapy
- •Measurable or evaluable disease
- •Previously received high-dose interleukin-2 OR have a contraindication for this treatment
- •No previously untreated or unstable brain metastases
- •No splenic metastasis
- •PATIENT CHARACTERISTICS:
- •ECOG performance status 0-2
- •Life expectancy ≥ 3 months
- •Absolute neutrophil count > 1,000/mm^3
- •Platelet count > 100,000/mm^3
- •PT/PTT ≤ 1.5 times upper limit of normal (ULN)
- •Creatinine < 1.5 times ULN
- •AST and ALT < 2.5 times ULN
- •Conjugated (Direct) bilirubin ≤ 1.25 times ULN
- •Not pregnant or nursing
- •Negative pregnancy test
- •Fertile patients must use effective contraception
- •LVEF ≥ 45% by cardiac stress test (e.g., stress thallium, stress MUGA, dobutamine echocardiogram, or other stress test) for patients meeting any of the following criteria:
- •History of ECG abnormalities
- •Symptoms of cardiac ischemia
- •At least 50 years of age and over
- •Familial or personal history of heart failure
- •Previously treated with antimitotic agents susceptible to trigger heart failure
- •FEV_1 > 60% of predicted (for patients with a prolonged smoking history or symptoms of respiratory dysfunction)
- •No concurrent cognitive impairment or likelihood of developing cognitive impairment on study therapy
- •No concurrent splenomegaly or proliferative hematologic disease
- •No documented HIV positivity
- •No acute hepatitis A or hepatitis B or C
- •Positive hepatitis B serology indicative of previous immunization (i.e., HBs Ab positive and HBc Ab negative) allowed
- •Positive hepatitis C serology allowed provided HCV RNA load by PCR is negative
- •Resting blood pressure ≤ 140/90 mm Hg on standard antihypertensive therapy
- •Untreated hypertensive patients who received standard antihypertensive therapy allowed provided hypertension is well controlled
- •No QTc prolongation ≥ 470 msec
- •No prior history of cardiovascular disease, arrhythmias, or significant ECG abnormalities
- •No active infection requiring systemic treatment and/or hospitalization within the past 28 days
- •Patients who have completed therapy or are clinically stable on therapy, in the opinion of the investigator, are eligible
- •No history of autoimmune disease
- •No history of severe asthma
- •No history of medical or psychiatric disease that would preclude study treatment
- •No documented cirrhosis or documented acute hepatitis
- •PRIOR CONCURRENT THERAPY:
- •See Disease Characteristics
- •More than 2 weeks since prior systemic corticosteroid therapy
- •More than 4 weeks since prior and no other concurrent cytotoxic therapy, immunotherapy, biological agents (i.e., cytokines, growth factors, or monoclonal antibodies), or antitumor vaccines
- •More than 7 days since prior hepatotoxic drugs unless medically necessary
- +10 more not shown
Exclusion Criteria
- Not provided
Arms & Interventions
CYT107 (r-hIL-7)
Experimental
Intervention: flow cytometry (Other)
CYT107 (r-hIL-7)
Experimental
Intervention: immunoenzyme technique (Other)
CYT107 (r-hIL-7)
Experimental
Intervention: immunologic technique (Other)
CYT107 (r-hIL-7)
Experimental
Intervention: laboratory biomarker analysis (Other)
CYT107 (r-hIL-7)
Experimental
Intervention: pharmacological study (Other)
CYT107 (r-hIL-7)
Experimental
Intervention: gene expression analysis (Genetic)
CYT107 (r-hIL-7)
Experimental
Intervention: polymerase chain reaction (Genetic)
CYT107 (r-hIL-7)
Experimental
Intervention: protein expression analysis (Genetic)
CYT107 (r-hIL-7)
Experimental
Intervention: recombinant interleukin-7 (Biological)
Outcomes
Primary Outcomes
Safety of recombinant interleukin-7 (IL-7)
Secondary Outcomes
- Pharmacokinetics and pharmacodynamics of IL-7
- Comparison of the biological and clinical effects of recombinant IL-7 with non glycosylated IL-7
- Potential antitumor effect of recombinant IL-7
- Dose and administration schedule of recombinant IL-7
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 1
Interleukin-7 in Treating Patients With Refractory Solid TumorsUnspecified Adult Solid Tumor, Protocol SpecificNCT00062049National Institutes of Health Clinical Center (CC)30
Completed
Phase 1
Interleukin-7 and Vaccine Therapy in Treating Patients With Metastatic MelanomaMelanoma (Skin)NCT00091338National Cancer Institute (NCI)
Completed
Phase 1
Interleukin-2 in Treating Patients With Mycosis FungoidesLymphomaNCT00002687University of Washington30
Completed
Phase 1
LMB-7 Immunotoxin in Treating Patients With Leptomeningeal MetastasesBrain and Central Nervous System TumorsNCT00003020Duke University24
Terminated
Phase 2
Study on Interleukin-7 (CYT107) in HIV PatientsHIVNCT01190111Cytheris SA23